Introduction {#sec1}
============

Invasive fungal diseases (IFDs) are significant causes of morbidity and mortality in patients with decreased immune function.^[@bib1]^ IFDs of the central nervous system (CNS) typically originate from a primary site outside of the nervous system or occur after invasive procedures such as neurosurgical or vascular intervention.^[@bib1]^ CNS involvement is common in *Cryptococcus* infections,^[@bib4]^ but rare for most other fungal species. However, the incidence is increasing with more widespread use of novel antineoplastic agents.^[@bib5]^ In addition, some fungi (e.g., *Cladophialophora bantiana*) exhibit neurotropism, causing CNS infections in healthy individuals.^[@bib8]^

Diagnostic confirmation of IFD of the CNS is frequently challenging, as cerebrospinal fluid often has a low yield for infecting pathogens,^[@bib11]^ while tissue biopsy is invasive and frequently not feasible. Furthermore, treatment with antifungal agents is frequently compromised by resistance and limited CNS penetration.^[@bib1]^ As such, CNS IFDs frequently progress rapidly and are associated with high mortality rates.^[@bib1],[@bib12]^

Combination therapy with amphotericin B and flucytosine remains the optimal initial approach in cryptococcal meningitis.^[@bib3],[@bib13]^ However, amphotericin B displays limited CNS penetration, is associated with toxicity, including renal adverse events, and is largely ineffective in CNS mould infections.^[@bib14]^ Among azoles, fluconazole is effective against *Cryptococcus* and *Candida* spp., whereas voriconazole has good CNS penetration and has been shown to be effective against a broad spectrum of fungal pathogens but is ineffective against Mucorales.^[@bib12],[@bib17]^

Isavuconazole is a novel triazole with a similar mode of action to voriconazole but with broad-spectrum activity encompassing a wider range of fungal species, including Mucorales. Isavuconazole demonstrates blood--brain barrier penetration in animal models,^[@bib18]^ and clinical efficacy has been reported in a single patient with disseminated mucormycosis and CNS involvement, who was treated with isavuconazole under the Emergency Investigational New Drug program.^[@bib19]^ The phase III VITAL trial (NCT00634049) evaluated isavuconazole as primary therapy in patients infected with rare fungi, principally mucormycosis, or renally impaired patients with aspergillosis.^[@bib20]^ A subgroup analysis of this trial evaluated the efficacy of isavuconazole against *Cryptococcus* species and dimorphic fungi.^[@bib21]^ The phase III SECURE trial (NCT00412893) compared isavuconazole with voriconazole as a primary treatment for infections caused by *Aspergillus* species or other filamentous fungi.^[@bib22]^ Isavuconazole was also made available as part of a named patient program (NPP), ahead of country-specific approvals for use in IFD.^[@bib23],[@bib24]^

The aim of this analysis was to assess the effectiveness of isavuconazole in the treatment of CNS IFDs, by examining relevant cases from the two isavuconazole phase III clinical trials and the NPP.

Methods {#sec2}
=======

Data were collated from the VITAL^[@bib20]^ and SECURE trials^[@bib22]^ as well as from the NPP. Disseminated IFD or CNS IFD were regarded as proven by histopathology or culture of fungal species from sterile body sites including cerebrospinal fluid, brain fine-needle aspiration, or brain biopsy using EORTC/(Mycoses Study Group \[MSG\] criteria.^[@bib25]^ In both trials, patients with probable IFD were also included. For cases of probable disseminated IFD, confirmation by CNS imaging, either by magnetic resonance imaging (MRI) or computed tomography (CT), in conjunction with a positive direct or indirect mycology test from another site (blood, sinus, lower respiratory tract), was regarded as evidence of CNS involvement. Both trials and the NPP excluded patients with *Candida* infections.

Adult dosages were consistent with the prescribing information. In pediatric patients, the dosages varied and were adjusted to maintain a target trough plasma level of 2000--4000 ng/ml (the approximate average adult trough plasma level observed in phase III studies).^[@bib23],[@bib24]^

Data regarding patient demographics, treatments, and outcomes were recorded and summarized. The primary outcome measure was the overall rate of survival at day 42 and day 84. Additionally, overall response based on clinical, mycological, and radiological response was examined, as assessed by a data review committee for the clinical trials,^[@bib20],[@bib22]^ or assessed by the treating physicians for NPP patients.

Results {#sec3}
=======

In total, 36 patient cases were identified from the relevant studies. This included 23 of 146 patients from the VITAL study, four of 516 patients from the SECURE study who were randomized to the isavuconazole arm, and nine of 101 patients from the NPP. From the NPP, three pediatric patients were included.^[@bib23],[@bib24]^ The demographic and baseline clinical characteristics of the included patients are provided in Table [1](#tbl1){ref-type="table"}.

###### 

Demographic and baseline clinical characteristics, and associated survival.

                                                                                         Survival    
  ------------------------------------------------------------------------- ------------ ----------- -----------
  Age, years:                                                                                        
   Median (range)                                                           51 (3--82)   NA          NA
   \<18                                                                     3 (8.3)      3 (100)     3 (100)
  Male sex                                                                  21 (58.3)    14 (66.7)   13 (61.9)
  Underlying conditions:                                                                             
   Hematologic malignancy                                                   17 (47.2)    12 (70.6)   9 (52.9)
    Allogeneic HCT                                                          5 (13.9)     3 (60.0)    2 (40.0)
   Use of corticosteroids                                                   9 (25.0)     9 (100)     8 (88.9)
   Neutropenia                                                              9 (25.0)     7 (77.8)    6 (66.7)
   Diabetes mellitus                                                        5 (13.9)     4 (80.0)    4 (80.0)
   Solid organ transplant                                                   3 (8.3)      3 (100)     2 (66.7)
   Penetrating trauma                                                       2 (5.6)      2 (100)     2 (100)
   Other[^b^](#tb1fn2){ref-type="table-fn"}                                 4 (11.1)     4 (100)     4 (100)
   None (at time of initial infection)[^c^](#tb1fn3){ref-type="table-fn"}   5 (13.9)     4 (80.0)    4 (80.0)

Data are proportion (%) of patients, unless otherwise specified. Underlying condition counts total to more than 36, because patients may have more than one underlying condition.

HCT = hematopoietic stem cell transplantation, NA = not applicable.

^a^Percentages are numbers of patients with the characteristic who were alive at day 42 or day 84/total numbers with the characteristic.

^b^Includes one each of: cell-mediated immune deficiency (uncontrolled), Crohn\'s disease, interstitial lung disease, and systemic lupus erythematosus.

^c^Includes patients who had infections caused by *Cryptococcus gattii* (three), *Exophiala* species (one), and *Paracoccidioides brasiliensis* (one).

Eight patients had meningitis, caused by *Cryptococcus* species in five patients (*C. gattii* in three, *C. neoformans* in two), *Exserohilum rostratum* in two patients, and *Exophiala* species in one patient. Twenty-eight patients had brain abscesses. Proven CNS IFD was documented in 33 patients (91.7%), with probable infections in the remaining three patients (Table [2](#tbl2){ref-type="table"}). All three patients with probable infections had CNS involvement (rhinocerebral disease) with positive culture from paranasal sinuses. Two of these patients were subsequently assessed using brain MRI; one of these patients had extensive sinusitis combined with bilateral frontal intracranial abscesses with extension into the brain parenchyma (Fig. [1](#fig1){ref-type="fig"}); the other patient had pansinusitis, with fluid and fat stranding in the extraocular space, abnormal hyperintensity involving the extraocular muscles, and acute infarct in the right medial temporal region. The third patient\'s infection was subsequently confirmed by brain CT, which showed sinusitis combined with intracranial bleeding. Lower respiratory tract disease (LRTD) was identified in 12 patients (33.3%), with a difference in proportions between patients receiving primary therapy (9/20, 45.0%) compared with salvage therapy (3/16, 23.1%).

![Axial (A) and sagittal (B) MRI scans of extensive sinusitis combined with bilateral frontal intracranial abscesses in a single patient. MRI = magnetic resonance imaging.](myz103fig1){#fig1}

###### 

Disease categorization, lower respiratory tract involvement, therapy status, and associated survival.

                                                     Survival    
  -------------------------------------- ----------- ----------- -----------
  Disease categorization:                                        
   Proven                                33 (91.7)   27 (81.8)   24 (72.7)
   Probable                              3 (8.3)     2 (66.7)    1 (33.3)
  Lower respiratory tract involvement:                           
   Yes                                   12 (33.3)   7 (58.3)    6 (50.0)
   No                                    24 (66.7)   22 (91.7)   19 (79.2)
  Therapy status:                                                
   Primary                               20 (55.6)   14 (70.0)   11 (55.0)
   Salvage (refractory)                  11 (30.6)   10 (90.9)   9 (81.8)
   Salvage (intolerant)                  2 (5.6)     2 (100)     2 (100)
   Salvage (refractory and intolerant)   3 (8.3)     3 (100)     3 (100)

^a^Percentages are numbers of patients with the site of infection who were alive at day 42 or day 84/total numbers with the site of infection.

Isavuconazole was administered as the primary therapy to 20 patients (55.6%), and as salvage therapy to 16 patients (44.4%). The median duration of isavuconazole therapy was 103.5 days (range, 2--882 days). Patients were switched to isavuconazole oral therapy after a median duration of 13.5 days (range, 2--91 days) of isavuconazole intravenous therapy.

Mucorales (11 patients; 30.6%) and *Aspergillus* species (8 patients; 22.2%) were the most commonly isolated types of fungi (Table [3](#tbl3){ref-type="table"}). *Cryptococcus* species were observed in five patients (13.9%), and dimorphic fungi (*Histoplasma capsulatum* and *Paracoccidioides brasiliensis*) accounted for infections in one patient each (5.6% in total). Mixed infections were observed in three patients (8.3%), with *Aspergillus* species involved in each case as one of the IFD-causing organisms. Other rare moulds (*C. bantiana, E. rostratum, Exophiala* species, and other nonspeciated moulds) were observed in 16.7% of patients. At a species level, *Aspergillus fumigatus* and *Rhizopus oryzae* were the most common fungi identified, both appearing in five patients (13.9%). For *A. fumigatus*, four cases were monoinfections, and one case was a mixed infection accompanied by *Verticillium tricorpus*; all of the *R. oryzae* cases were monoinfections.

###### 

Mycological findings.

                                                                             Survival   
  -------------------------------------------------------------- ----------- ---------- ----------
  *Aspergillus* species                                          8 (22.2)    7 (87.5)   5 (62.5)
   *Aspergillus fumigatus*                                       4 (11.1)    4 (100)    4 (100)
   *Aspergillus flavus*                                          2 (5.6)     2 (100)    1 (50.0)
   *Aspergillus flavus* and *Aspergillus terreus*                1 (2.8)     0 (0)      0 (0)
   Not speciated                                                 1 (2.8)     1 (100)    0 (0)
  *Cryptococcus* species                                         5 (13.9)    5 (100)    5 (100)
   *Cryptococcus gattii*                                         3 (8.3)     3 (100)    3 (100)
   *Cryptococcus neoformans*                                     2 (5.6)     2 (100)    2 (100)
  Dimorphic fungi                                                2 (5.6)     1 (50.0)   1 (50.0)
   *Histoplasma capsulatum*                                      1 (2.8)     1 (100)    1 (100)
   *Paracoccidioides brasiliensis*                               1 (2.8)     0 (0)      0 (0)
  Mucorales                                                      11 (30.6)   7 (63.6)   7 (63.6)
   *Rhizopus oryzae*                                             5 (13.9)    3 (60.0)   3 (60.0)
   *Rhizomucor pusillus*                                         1 (2.8)     0 (0)      0 (0)
   *Mucor* species (not speciated)                               1 (2.8)     0 (0)      0 (0)
   *Lichtheimia* species (not speciated)                         1 (2.8)     1 (100)    1 (100)
   Mucorales (not otherwise specified)                           3 (8.3)     3 (100)    3 (100)
  Mixed infection                                                3 (8.3)     2 (66.7)   1 (33.3)
   *Aspergillus terreus* and *Lichtheimia corymbifera*           1 (2.8)     0 (0)      0 (0)
   *Aspergillus fumigatus* and *Verticillium tricorpus*          1 (2.8)     1 (100)    0 (0)
   *Aspergillus niger* and Mucorales (not otherwise specified)   1 (2.8)     1 (100)    1 (100)
  Other moulds                                                   6 (16.7)    6 (100)    5 (83.3)
   *Cladophialophora bantiana*                                   2 (5.6)     2 (100)    1 (50.0)
   *Exserohilum rostratum*                                       2 (5.6)     2 (100)    2 (100)
   *Exophiala* species                                           1 (2.8)     1 (100)    1 (100)
   Not speciated                                                 1 (2.8)     1 (100)    1 (100)

^a^Percentages are numbers of patients with the fungal organism who were alive at day 42 or day 84/total numbers with the fungal organism.

At the end of treatment, complete or partial clinical responses were achieved in 58.3% of patients (Table [4](#tbl4){ref-type="table"}). Overall response rates were lower, with 36.1% of patients achieving a complete or partial overall response at the end of treatment. However, it should be noted that this is a composite endpoint of clinical, mycological, and radiological response, and that radiological response was previously noted to lag behind clinical improvement in both clinical trials.^[@bib20],[@bib22]^

###### 

Clinical outcomes.

  Outcome                                                                     N = 36 *n* (%)
  --------------------------------------------------------------------------- ----------------
  Clinical response[^a^](#tb4fn1){ref-type="table-fn"} at end-of-treatment:   
   Complete/partial                                                           21 (58.3)
    Complete                                                                  11 (30.6)
    Partial                                                                   10 (27.8)
   Failure                                                                    15 (41.7)
  Overall response[^b^](#tb4fn2){ref-type="table-fn"} at end-of-treatment:    
   Complete                                                                   7 (19.4)
   Partial                                                                    6 (16.7)
   Stable                                                                     6 (16.7)
   Progression                                                                17 (47.2)
  Survival at day 42                                                          29 (80.6)
  Survival at day 84                                                          25 (69.4)

^a^Clinical response is defined as the resolution or partial resolution of all attributable clinical symptoms and physical findings.

^b^Overall response was based on a composite of clinical, mycological, and radiological response as assessed by a data review committee or the treating physicians for patients in the named-patient program.

The overall survival rate was 80.6% at day 42 and 69.4% at day 84. The overall probability of survival at day 183 was 61.6% (Fig. [2](#fig2){ref-type="fig"}). By day 42, seven patients had died: six patients died due to the consequences of progressive IFD, and one patient died from pseudomonal pneumonia. Survival varied according to patient demographics and disease characteristics. The lowest survival rate was observed in patients with hematologic malignancies (*n* = 17; day 42: 70.6%; day 84: 52.9%), and a survival rate of \< 80% was also observed in patients with neutropenia (*n* = 9; day 42: 77.8%; day 84: 66.7%) or solid organ transplant (*n* = 3; day 42: 100%; day 84: 66.7%) (Table [1](#tbl1){ref-type="table"}). Survival was higher in female patients than in male patients (day 42: 100% vs. 66.7%; day 84: 80.0% vs. 61.9%).

![Kaplan--Meier survival curve of 36 patients receiving isavuconazole treatment for fungal infections of the CNS. CNS = central nervous system.](myz103fig2){#fig2}

The presence of lower respiratory tract involvement was associated with reduced survival. In patients with LRTD, survival was 58.3% at day 42 and 50.0% at day 84. In the absence of LRTD, survival was 91.7% at day 42 and 79.2% at day 84 (Table [2](#tbl2){ref-type="table"}). Survival rates differed according to the line of therapy in which isavuconazole was used. When used as primary therapy, the overall survival rate was 70.0% at day 42 and 55.0% at day 84. In contrast, overall survival rates were higher in patients who received isavuconazole as salvage therapy (day 42: 93.8%; day 84: 87.5%).

Survival rates were also impacted by the varying types of infecting fungi (Table [3](#tbl3){ref-type="table"}), although patient numbers were low for some genera. The highest rates of survival (100% survival at day 42 and day 84) were observed in patients with *Cryptococcus* infections and infections caused by the rare moulds *Cladophialophora, Exserohilum*, and *Exophiala* species, among others. Lower rates of survival were observed with *Aspergillus* species (day 42: 87.5%; day 84: 62.5%) and Mucorales (days 42 and 84: 63.6%).

In 25 patients (69.4%), surgical interventions other than brain biopsy were used in addition to isavuconazole treatment (Table [5](#tbl5){ref-type="table"}). In 12 patients, these were direct neurological interventions: repeat lumbar punctures or craniotomy with or without abscess resection. The other 13 patients received sinus or nasal surgery, mastoidectomy or facial resection. Survival rates associated with surgical intervention were numerically higher compared with patients where surgical intervention was not employed (day 42: 80.0% with surgery vs. 75.0% without; day 84: 68.0% with surgery vs. 62.5% without).

###### 

Surgical interventions.

                                                                            Survival    
  ------------------------------------------------------------- ----------- ----------- -----------
  Any intervention                                              25 (69.4)   20 (80.0)   17 (68.0)
   Sinus or nasal surgery                                       10 (27.8)   7 (70.0)    6 (60.0)
   Repeat lumbar punctures[^c^](#tb5fn3){ref-type="table-fn"}   7 (19.4)    7 (100)     7 (100)
   Craniotomy ± abscess resection                               5 (13.9)    4 (80.0)    3 (60.0)
   Mastoidectomy                                                2 (5.6)     2 (100)     1 (50.0)
   Facial resection                                             1 (2.8)     0 (0)       0 (0)
  None                                                          8 (22.2)    6 (75.0)    5 (62.5)

^a^No information was available for three patients.

^b^Percentages are numbers of patients with the fungal organism who were alive at day 42 or 84/total numbers with the intervention.

^c^No information available on whether these were performed for diagnostic or therapeutic purposes.

Discussion {#sec4}
==========

This analysis provides evidence of the effectiveness of isavuconazole as a treatment for IFDs with CNS involvement. Overall, survival rates were 80.6% at day 42 and 69.4% at day 84. The presence of hematologic malignancy was associated with a lower survival rate, which is consistent with previous studies of CNS IFD in patients receiving hematopoietic stem cell transplantation (HCT).^[@bib2],[@bib12]^ Improved survival was observed in female patients compared with male patients, which might be explained by microbiological differences, given the higher proportion of Mucorales infections among males. These infections are known to have an aggressive clinical course,^[@bib26]^ complicated by frequent resistance to some commonly used antifungal agents.^[@bib27]^

A higher survival rate was also observed in patients receiving isavuconazole as salvage therapy compared with primary therapy, a somewhat unexpected finding as patients receiving salvage therapy would be more likely to have advanced disease than patients receiving primary therapy. This finding may be explained by a selection bias: patients who survived long enough to be switched to isavuconazole would potentially have less severe illness than those who did not survive to receive a second-line therapy. An alternative explanation is that a substantially greater proportion of patients receiving isavuconazole as primary therapy had LRTD (45.0%), and therefore a worse prognosis, compared with patients receiving salvage isavuconazole (18.8%). Involvement of the respiratory tract appeared to be associated with lower survival, although no obvious microbiological differences were noted between those with or without LRTD. This location of IFD, caused by inhalation of fungi as the first step of infection, can be the source of a disseminated and more complex course of fungal disease also including the CNS.^[@bib28]^ The effectiveness of isavuconazole as salvage therapy for infections of the CNS was also assessed in a retrospective series of patients with coccidioidal meningitis.^[@bib29]^ A total of nine patients were initially treated with fluconazole and switched to voriconazole. All nine patients subsequently received isavuconazole as salvage therapy, with the majority of voriconazole patients switching to isavuconazole due to adverse events (one patient switched after voriconazole treatment failure). All nine patients achieved treatment success (three patients) or stable disease (six patients) during a follow-up with isavuconazole therapy ranging from 138 to 810 days. These data further support the utility of isavuconazole in fungal infections of the CNS.

In the present retrospective study, treatment with isavuconazole was effective against CNS infections caused by a wide range of different fungi. Our data also support previous animal studies that showed effective penetration of isavuconazole across the blood--brain barrier.^[@bib18]^ These findings have recently been augmented by a case report demonstrating adequate brain tissue penetration for isavuconazole in a patient with invasive cerebral aspergillosis, although the level in abscess fluid was low.^[@bib30]^ Another recent study reported higher concentrations of isavuconazole in inflammatory brain tissue compared with healthy brain tissue in two patients with *A. fumigatus* infections. In one patient, the concentration in inflammatory brain tissue also exceeded the plasma concentration.^[@bib31]^ No pharmacokinetic data on brain penetration are available from our current study, although trough plasma concentrations have been reported previously.^[@bib20],[@bib22]^ An analysis comparing mean trough concentrations between participants in SECURE who received at least one dose of isavuconazole found no concentration-dependent relationships for efficacy or safety.^[@bib32]^ Furthermore, a relationship between trough isavuconazole plasma concentrations, fungal isolate minimum inhibitory concentrations, and key outcomes could not be identified in VITAL, although this may have been due to the small number of patients with data available.^[@bib20]^ Therefore, additional clinical data in different localizations and stages of infection are needed to better understand brain tissue and CNS fluid penetration of this azole.

Voriconazole is another azole used for the treatment of invasive fungal infections, for which effectiveness against CNS IFD was evaluated in an analysis similar to the current study.^[@bib33]^ A total of 192 cases were accumulated from the voriconazole clinical trial database and published case reports and case series. Treatment with voriconazole resulted in complete or partial responses in 63% of cases as primary therapy and 45% of cases as salvage therapy, and outcomes improved significantly with antifungal combination therapy and with surgery. These results were largely similar to those observed in the current study, in which isavuconazole achieved a complete or partial response in 50.0% of patients as primary therapy and 68.8% as salvage therapy. However, this comparison must be interpreted with caution because of epidemiological differences across the two retrospective cohorts. In the voriconazole study, there was a higher proportion of cases involving *Aspergillus* species (62.5% vs. 22.2% in the current study) and no cases of mucormycosis, which is particularly relevant given the lack of activity of voriconazole against Mucorales.^[@bib27]^ In addition, the voriconazole study included more pediatric patients (21.4% vs. 8.3%), and a lower proportion of cases with hematologic malignancy as an underlying condition (18.2% vs. 47.2%), compared with the current study. Clinical responses were more frequently observed in published versus database cases treated with voriconazole for CNS IFD suggesting a publication bias. A publication bias is unlikely true for the present analysis as we have included patients from clinical databases only.

In an earlier study that retrospectively analyzed the effectiveness of voriconazole in 81 patients with *Aspergillus* infections of the CNS,^[@bib34]^ the survival rate was 31%. While this is lower than the survival rate in *Aspergillus* infections observed in the current analysis (day 42: 87.5%; day 84: 62.5%), comparisons may not be meaningful because of differences in study populations and the considerable time that has elapsed between the studies, which may have allowed for improvements in other aspects of care. In SECURE,^[@bib22]^ only two patients were treated with voriconazole for infections with CNS involvement, both as primary therapy. A partial clinical response was achieved in one patient infected with *Aspergillus* spp. who subsequently died on day 77, whereas one patient infected with *A. fumigatus* experienced treatment failure but survived.

Posaconazole has also been studied as a salvage therapy option for CNS IFD. In a multinational, multicenter, open-label clinical trial, 39 evaluable patients received posaconazole for CNS IFD, 29 of whom had human immunodeficiency virus infection as the underlying condition. Of the evaluable patients, 14 of 29 (48%) with cryptococcal meningitis and five of 10 (50%) with other fungal pathogens had successful outcomes. Of the 10 patients with other fungal pathogens, four patients had *Aspergillus* infections, and one patient had mucormycosis (*Apophysomyces elegans*) combined with a *Basidiomycetes* spp. infection. Treatment was partially successful in one case (*A. fumigatus*), and three of the four remaining patients died within 2 weeks of posaconazole treatment initiation.^[@bib35]^ While the results of our analysis appear more favorable, in addition to the time elapsed between studies, the differences in underlying conditions makes a meaningful comparison difficult.

In two later analyses, posaconazole treatment for patients with mucormycosis and brain lesions achieved partial or complete responses in two out of four (50%) patients in two open-label trials^[@bib36]^ and in eight out of 11 (72.7%) patients receiving treatment under a compassionate-use program.^[@bib37]^ More recently, a review analyzed 96 cases of mucormycosis treated with posaconazole as salvage therapy. Of the seven patients whose infections were reported to have definite CNS involvement, three had complete responses, one had a partial response, one remained stable, and two died.^[@bib38]^ The underlying causes for infection in these summaries are consistent with our analysis, and our results are comparable for mucormycosis. However, posaconazole penetration of the CNS has been reported to be poor.^[@bib39]^ While there is evidence to suggest that CNS penetration of posaconazole may improve with inflammatory disruption of the blood--brain barrier,^[@bib40]^ this was not supported by a recent study in a patient with cerebral phaeohyphomycosis.^[@bib41]^

In the current analysis, surgical intervention seemed to be associated with a modest benefit in overall survival. Previous research has shown a significant benefit of neurosurgery in the treatment of CNS IFD caused by a broad spectrum of species.^[@bib33]^ In the current study, the conditions under which surgery was used and the types of surgery selected were highly variable, which may have impacted the overall benefit observed. In addition, seven of the patients in our analysis underwent repeated lumbar punctures, but it is not known whether these were intended therapeutically (e.g., to alleviate increased intracranial pressure) or were performed for diagnostic purposes. However, as five of these patients had *Cryptococcus* infections, it should be noted that controlling intracranial pressure in cryptococcal meningitis is mandatory.^[@bib3],[@bib13]^ A further reason for differences may be that infections amenable to surgical treatment (e.g., brain abscess, rhinocerebral mucormycosis) are most probably different compared with infections without surgical options (e.g., cryptococcal meningitis). A previous study in patients undergoing HCT found that many patients were considered ineligible for surgery.^[@bib2]^ The high proportion of patients with hematologic malignancies in our analysis may partially explain the limited use and effect of surgery.

Overall, our findings should be interpreted with caution as our analysis featured a relatively low number of highly selected patients and was retrospective in nature. Furthermore, this analysis included data from two different trials and a separate database and covered a range of fungal pathogens.

Our report suggests that isavuconazole may be a valuable option in the treatment of CNS IFDs. To improve outcomes, future research should focus on advances in diagnostic methods (e.g., molecular detection, fungus identification with susceptibility testing), CNS pharmacokinetics of antifungal compounds, development of antifungal compounds with enhanced CNS-directed efficacy, and further investigation of crucial host defense mechanisms.
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